このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

HER2陽性またはトリプルネガティブ乳がん患者の治療における全身療法後の手術または放射線療法の排除

2026年9月23日 更新者:M.D. Anderson Cancer Center

ネオアジュバント全身療法に対する例外的なレスポンダーにおける乳がん手術または放射線療法を排除するための多施設試験

This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual cancer, patients then receive standard breast radiotherapy with no surgery. In ER positive/HER2 negative breast cancers, after endocrine therapy and ablative radiotherapy, when image-guided biopsy shows no residual cancer, patients then receive standard endocrine therapy with no surgery. For patients who have HER2 positive and triple negative breast cancers and standard surgery, after systemic therapy, breast radiotherapy is being eliminated when the pathology from surgery shows no residual cancer.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. Cohort A1 and A2: To determine the 6 mo, 1, 2, 3, 5, 7, and 10 year biopsy confirmed ipsilateral breast tumor recurrence rate (IBTR, invasive and/or in situ) among patients who do not undergo surgery.

II. Cohort B: To determine the pCR rate 6 or 12 months after radiation therapy based on image-guided biopsy.

III. Cohort C: To determine the 6 mo, 1, 2, 3, 5, 7 and 10-year ipsilateral breast tumor recurrence rate among patients who undergo surgery alone without radiation.

SECONDARY OBJECTIVES:

I. Cohort B: To determine the 6 mo, 1, 2, 3, 5, 7 and 10--year biopsy confirmed ipsilateral breast tumor recurrence rate (IBTR, invasive and/or in situ) among patients who do not undergo surgery.

II. To determine the number (%) of patients where final biopsy reveals residual disease and quantify the residual disease (residual cancer burden, RCB) determined by routine pathologic examination of surgery specimens.

III. To assess baseline, 6 months, 1, 3, 5, 7, and 10 years decisional comfort of clinical trial participation using the Decisional Regret Scale (DRS).

IV. To determine patient-reported cosmetic outcome, breast pain, and functional status using the Breast Cancer Treatment Outcomes Scale (BCTOS) at baseline, 6 months, 1, 3, 5, 7, and 10 years.

V. To determine the 6 mo, 1, 2, 3, 5, 7, and 10 years incidence of ipsilateral breast and nodal recommendation and performance of biopsy based on breast imaging follow-up.

VI. Correlate "liquid biopsy" analyses (after standard routine NST, 6 months and one year post-radiotherapy or surgery) among protocol participants with pCR, utilizing circulating tumor cells (CTCs) and circulating tumor-DNA (ctDNA).

VII. Among patients who decide to proceed with routine surgery, record the results of final biopsy compared with routine pathologic examination of surgery specimens.

VIII. To determine patient-reported quality of life using the FACT B+4 instrument at baseline, 6 months, 1, 3, 5, 7, and 10 years after treatment.

IX. To explore if radiation genomic sensitivity scores and Oncotype performed on the initial diagnostic core biopsy specimen correlate with pCR rates in Cohort B.

X. To determine if changes in blood-based RNA Sequencing are elicited with radiation in Cohort B, measured at baseline, at the first 4-6 week follow-up after radiation, and at the 6 month post-radiation follow-up.

XI. In Cohort B to determine the 3-year rate of tumor control/ progression free survival (PFS).

XII. In Cohort C/D to determine whether nanomechanical biomarkers or quantification of stromal and tumor TILS can predict for low risk of local recurrence in exceptional responders who omit radiation therapy.

XIII. In Cohorts A/B/C/D: To record 6 mo, 1, 2, 3, 5, 7, and 10 year breast cancer disease-free and overall survival.

XIV. In Cohort D: Correlate nanomechanical biomarker analyses with pCR and/or local recurrence in patients with triple negative or her-2 positive breast cancer treated with lumpectomy +/- radiation.

OUTLINE:

For Cohorts A, within 12 weeks of completing neoadjuvant systemic therapy, patients undergo whole breast irradiation over 15-25 fractions on consecutive days. Patients then undergo external beam radiation therapy (EBRT) boost over 7 fractions on consecutive days beginning the day following completion of whole breast irradiation.

For Cohort B, patients will receive 3 months of neoadjuvant endocrine therapy, after which they will receive ablative partial breast irradiation over 5 fractions. Patients will then continue with endocrine therapy.

After completion of study treatment, patients are followed up every 6 months for 10 years.

研究の種類

介入

入学 (推定)

120

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Arizona
      • Gilbert、Arizona、アメリカ、85234
        • 完了
        • MD Anderson Cancer Center - Banner
    • Florida
      • Jacksonville、Florida、アメリカ、32207
        • 募集
        • Baptist MD Anderson Cancer Center
        • 主任研究者:
          • Beth A. Lesnikoski
        • コンタクト:
    • Hawaii
      • Honolulu、Hawaii、アメリカ、96813
        • 完了
        • Queen's Medical Center
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic
        • コンタクト:
        • 主任研究者:
          • Judy C. Boughey
    • New Jersey
      • Voorhees Township、New Jersey、アメリカ、08103
        • 募集
        • Cooper Hospital Univ Med Ctr, MD Anderson at Cooper Voorhees
        • コンタクト:
        • 主任研究者:
          • Catherine E. Loveland-Jones
    • North Carolina
      • Charlotte、North Carolina、アメリカ、28203
        • 募集
        • Carolinas Medical Center/Levine Cancer Institute
        • コンタクト:
        • 主任研究者:
          • Richard L. White
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • 募集
        • University of Pittsburgh Cancer Institute (UPCI)
        • コンタクト:
        • 主任研究者:
          • Emilia J. Diego
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • M D Anderson Cancer Center
        • コンタクト:
        • 主任研究者:
          • Henry M. Kuerer

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

30年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • Cohort A1 and A2

    • Conditions for patient eligibility: Patients on this portion of the study can receive radiation treatment at any MD Anderson Cancer Center or any outside hospital and may be enrolled prior to, during, or following neoadjuvant systemic therapy provided they meet the following eligibility and ineligibility requirements noted below:

    1. Pathologically confirmed unicentric invasive breast cancer defined as radiologic clinical stage T1 or T2 (≤ 5 cm), N0 or N1 (≤ 4 abnormal axillary nodes on initial ultrasound), clinical stage M0.
    2. HER2 positive (IHC 3+ and or FISH amplified) or triple receptor negative (TN, ER/PR< 10% HER2 negative (IHC 1+ or 2+ FISH non-amplified) receiving any standard routine clinical NST regimen.
    3. Patient desires breast conserving therapy.
    4. Age 40 years or older. This age cutoff is justified because breast cancers in women under the age of 40 are known to have a significantly higher risk of IBTR presumably due to underlying biologic differences [124, 125].
    5. Female sex.
    6. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer.
    7. Patient must have an initial nodal ultrasound that does not demonstrate more than four suspicious lymph nodes, any suspicious lymph nodes should be biopsied to determine if nodal metastatic disease present.
    8. Patient understands that the breast lesion size on final breast imaging must be less than or equal to 2 cm prior to the biopsy procedure being performed on study and if the biopsy shows residual carcinoma the patient will be taken off study.
  • Cohort B1 and B2

    • Conditions for patient eligibility: Patients on this portion of the study will be limited to receive radiation treatment at MD Anderson Cancer Center or other approved locations and must be enrolled prior to any neoadjuvant systemic therapy provided they meet the following eligibility and ineligibility requirements noted below:

    1. ER and/or PR positive, HER2 negative
    2. Clinical stage T1N0M0, unicentric non-lobular breast cancer, no lymphovascular space invasion,
    3. At least 40 years of age.
    4. Oncotype ≤ 25 if age ≥ 50 years
    5. Oncotype 0-20 and tumor size ≤ 1.5cm if age 40-49 years.
    6. Patient agrees to take anti-estrogen therapy and is interested in breast conservation
    7. Female sex.
    8. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer.
    9. No history of prior radiation to the area of the breast that would require protocol-mandated treatment
  • Cohort C

    • Conditions for patient eligibility: Patients on this portion of the study can receive surgical treatment at any MD Anderson Cancer Center or any outside hospital and may be enrolled prior to or following neoadjuvant systemic therapy provided they meet the following eligibility and ineligibility requirements noted below:

    1. Pathologically confirmed invasive breast cancer defined as radiologic clinical stage T1 or T2 (≤ 5 cm), N0, clinical stage M0 and HER2 positive (IHC 3+ and or FISH amplified) receiving any standard routine clinical NST regimen containing her-2 directed therapy OR Pathologically confirmed invasive breast cancer defined as radiologic clinical stage T1 (≤ 2 cm), N0, clinical stage M0 and triple negative, receiving any standard routine clinical NST regimen.
    2. For cohort C patients participating in the optional pretreatment biopsy, the patient should be able undergo biopsy or surgery of the primary tumor site of suspected or proven invasive breast cancer and should be planned to receive neoadjuvant systemic therapy.
    3. Patient desires breast conserving therapy.
    4. Age 30 years or older if HER2 positive. Age 50 or older if HER2 negative (triple negative).
    5. Female sex.
    6. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer.
    7. Patient must have an initial nodal ultrasound that does not demonstrate suspicious lymph nodes; any suspicious lymph nodes should be biopsied to determine if nodal metastatic disease present.
    8. Patient must have no evidence of residual invasive tumor or DCIS on pathologic review of the lumpectomy surgical specimen
    9. Patient must have no evidence of metastatic disease or isolated tumor cells involving the lymph nodes on pathologic review of the lymph node surgical specimen. If treatment effect in the nodes is noted on the pathology report, the investigators would generally discourage enrollment on this protocol.
    10. Unifocal disease or limited multifocal disease that can be excised in a single lumpectomy specimen
  • Cohort D (MD Anderson Houston patients only)

    • Conditions for patient eligibility: Patients on this portion of the study meet all eligibility requirements for cohort C, but have not enrolled onto the study to omit radiation. Patients in Cohort D can be identified at the time of diagnosis or prior to lumpectomy. They are not required to participate in one of the treatment arms of the study, but can ultimately choose to move to an omission Cohort at a later time point.

3.5.1 Patients with triple negative or her-2 positive tumor who are amenable to breast conserving treatment and have received or are planned for neoadjuvant systemic therapy prior to surgery are eligible for Cohort D.

3.5.2 Eligible patients in cohort D who have undergone optional ARTIDIS biopsies of the primary breast tumor at the time of diagnosis, prior to starting neoadjuvant therapy, or following completion of systemic therapy, at the time of surgery, may later move to Cohort A or C if they meet all eligibility requirements and ultimately desire surgery or radiation omission

Exclusion Criteria:

  1. Radiologic evidence for a stage T3 or clinical stage T4 breast cancer in Cohort A1/A2/C; radiologic evidence for a stage T2-T3 or clinical stage T4 breast cancer in Cohort B1/B2.
  2. Clinical or pathologic evidence for distant metastases.
  3. Prior diagnosis of invasive or ductal carcinoma in situ breast cancer in the ipsilateral breast.
  4. Clinical evidence of progression of disease >20% in the breast or new evidence of nodal metastases.
  5. Patient is known to be pregnant.
  6. Patient is participating in a NST protocol in which surgical excision of the breast and or lymph nodes are required in Cohort A1/A2/B1/B2.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort A
  • Neoadjuvant chemotherapy therapy
  • Biopsy: if no disease remaining - stay on the study and receive radiation (skip breast surgery)
  • H&P and Imaging every 6 months

Treatment (whole breast irradiation, EBRT) Within 12 weeks of completing neoadjuvant systemic therapy, patients undergo whole breast irradiation over 15-25 fractions on consecutive days. Patients then undergo EBRT boost over 7 fractions on consecutive days beginning the day following completion of whole breast irradiation.

Correlative studies

Ancillary studies

他の名前:
  • 生活の質の評価

Undergo EBRT

他の名前:
  • 根治的放射線療法
  • 外照射放射線治療
  • 外部ビーム RT
  • 外部放射線
  • 外照射療法
  • 外部ビーム放射
  • セイバー

Undergo partial breast irradiation

実験的:Cohort B

• Neoadjuvant endocrine therapy for 3 months

Cohort B Radiation:

Treatment (Stereotactic ablative radiotherapy -SABR) Following 3-6 months of endocrine therapy, if less than 25% tumor increase, patients undergo SABR irradiation over 5 fractions

  • Continued endocrine therapy for total of 5 years Biopsy 6-12months after radiation: if negative - additional endocrine therapy under the guidance of medical oncologist (skip breast surgery)
  • H&P and Imaging every 6 months

Correlative studies

Ancillary studies

他の名前:
  • 生活の質の評価

Ancillary studies

Undergo EBRT

他の名前:
  • 根治的放射線療法
  • 外照射放射線治療
  • 外部ビーム RT
  • 外部放射線
  • 外照射療法
  • 外部ビーム放射
  • セイバー

Undergo partial breast irradiation

実験的:Cohort C
  • Optional biopsy for nanomechanical biomarker assessment
  • Neoadjuvant chemotherapy therapy
  • Surgery (& optional biopsy nanomechanical biomarker assessment): if no disease remaining - stay on the study and skip radiation
  • H&P and Imaging every 6 months

Correlative studies

Ancillary studies

他の名前:
  • 生活の質の評価

Ancillary studies

実験的:Cohort D
  • Optional biopsy for nanomechanical biomarker assessment
  • Chart review every year after surgery for 5 years
  • Eligible patients who have undergone the optional biopsy may later move to Cohort A or C if they meet all eligibility requirements and desire radiation omission.

Ancillary studies

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Ipsilateral breast tumor recurrence-free survival (IBT-RFS)
時間枠:From confirmation of pathologic complete response (pCR) to the time of ipsilateral breast tumor recurrence or death, whichever occurs first or the time of last contact, assessed for up to 10 years

Will monitor IBT-RFS using the method of Thall et al. Will be estimated using the Kaplan-Meier method log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.

From confirmation of pathologic complete response (pCR) to the time of ipsilateral breast tumor recurrence or death, whichever occurs first or the time of last contact, assessed for up to 10 years
Overall survival
時間枠:Up to 10 years

Will be estimated using the Kaplan-Meier method log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.

Up to 10 years

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in biomarkers in blood and plasma
時間枠:3 months, 3-8 weeks post radiation therapy (if applicable), 6 months, 12 months]

Biomarkers in blood and plasma, specifically CTC and cDNA, will be assessed by exploratory data analysis and graphical methods, which will be applied to examine distributions and to identify data errors and outliers. Linear mixed effect models for repeated measures analysis will be employed to assess the change of the data over time with multi-covariates including disease characteristics (tumor stage, site, pathology), and other patient prognostic factors.

3 months, 3-8 weeks post radiation therapy (if applicable), 6 months, 12 months]
Residual cancer burden (RCB)
時間枠:Up to 10 years

Will be assessed by biopsy and routine surgery. Descriptive statistics will be used. The final biopsy will be compared with the response status determined by routine pathologic examination of surgery specimens using McNemar test.

Up to 10 years
Incidence of ipsilateral breast and nodal recommendation and performance of biopsy based on breast imaging follow-up
時間枠:Up to 10 years

Multivariable logistic regression analysis using generalized estimating equations to take the intra-patient correlation into account will be used to determine factors significantly associated with the outcome.

Up to 10 years
Quality of Life measured by DRS questionnaire
時間枠:Baseline, 6 months, 12 months, 36 months, 60 months, 84 months, and 120 months]

The Decisional Regret Scale (DRS) questionnaire will assess the decisional comfort of the clinical trial participant.

Question answers range : Strongly Agree, Agree, Neither Agree Nor Disagree, Disagree, or Strongly Agree

Baseline, 6 months, 12 months, 36 months, 60 months, 84 months, and 120 months]
Quality of Life measured by BCTOS questionnaire
時間枠:Baseline, 6 months, 12 months, 36 months, 60 months, 84 months, and 120 months]

The Breast Cancer Treatment Outcome Scale (BCTOS) will assess patient-reported cosmetic outcome, breast pain, and functional status by comparing the affected breast with her unaffected breast.

Baseline, 6 months, 12 months, 36 months, 60 months, 84 months, and 120 months]
Quality of Life measured by FACT-B+4 questionnaire
時間枠:Baseline, 6 months, 12 months, 36 months, 60 months, 84 months, and 120 months]

The FACT-B+4 will assess the general quality of life of the patient.

Baseline, 6 months, 12 months, 36 months, 60 months, 84 months, and 120 months]

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Henry M Kuerer、M.D. Anderson Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年1月20日

一次修了 (推定)

2028年1月31日

研究の完了 (推定)

2028年1月31日

試験登録日

最初に提出

2016年10月24日

QC基準を満たした最初の提出物

2016年10月24日

最初の投稿 (推定)

2016年10月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月23日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2016-0046
  • 2016-0046 (その他の識別子:M D Anderson Cancer Center)
  • NCI-2016-01929 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する